Brexit: chemical regulation

November 18, 2018

Although chemical regulation may seem like a niche area of Brexit considerations, chemicals are key components in products that we all use every day, and the UK exported £18 billion of chemicals to the EU in 2017. Both the chemical industry and the many supply chains that rely on it could be strongly affected if Brexit disrupts current arrangements. It is vital for both human and environmental health that these substances are regulated safely after Brexit, and in a way that allows chemical trade between the UK and EU to continue.

Spotlight

Verastem

Verastem, Inc. is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells.

OTHER WHITEPAPERS
news image

CARBOHYDRATE POLYMER TECHNOLOGIES AND APPLICATIONS

whitePaper | November 24, 2021

Carbohydrate Polymer Technologies and Applications is an open access scholarly journal devoted to scientific and technological aspects and applications of polymers and oligomers containing carbohydrate. Carbohydrate Polymer Technologies and Applications is a companion journal to Carbohydrate Polymers with a broader and more inclusive reach to cater for the increased spread of research interests.

Read More
news image

AQUAZOL STABILIZED HYDROGEN PEROXIDE

whitePaper | September 11, 2022

Hydrogen peroxide is a reagent used in many industries and this usage is growing especially where it is replacing reagents known or suspected of causing cancer and other long-term health problems.

Read More
news image

Addressing decarbonization at the grid edge

whitePaper | December 24, 2022

This whitepaper discusses decarbonization and how it affects consumers in the commercial and industrial (C&I) sector. It is based on expert insight and market interviews conducted during summer of 2020 and reflects Siemens’ and Delta-EE’s common view on the topic.

Read More
news image

Introduction to Edition II with comparative measurements

whitePaper | November 16, 2022

This white paper presents ABB’s new TSP341-N temperature sensor for non-invasive temperature measurement and provides examples for applications and accuracies that can be achieved.

Read More
news image

ChemDraw and Chemoffice+ Cloud tips and tricks v21

whitePaper | November 24, 2022

A long-time staple of ChemDraw, HOTKEYS – single keyboard key presses over an atom or a bond to elicit an action.

Read More
news image

Chain Reaction: Conquering Labeling Challenges in the Chemical Industry

whitePaper | February 28, 2020

Reversing the complexity of global labeling management in the chemicals industry, so that intensifying regulatory demands don’t encroach on international market opportunity Trust, transparency and, above all, the safety of process/supply-chain intermediaries and consumers, is of paramount importance to the global chemicals industry. Yet, increasingly-stringent regulations about product/substance-based declarations, hazard warnings, and use of mandatory safety statements and symbols, is taking its toll on international brands.

Read More

Spotlight

Verastem

Verastem, Inc. is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells.

Events